Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
27 July 2021 | Story Leonie Bolleurs | Photo UFS Photo Archive
Prof Hendrik Swart played a key role in the Department of Physics acquiring the PHI Quantes XPS system, the first in Africa and one of only 20 in the world.

The state-of-the-art equipment in the Department of Physics at the University of the Free State (UFS) differentiates this department from its competitors. Availability of the equipment makes it possible for researchers as well as students to deliver work that receives national and international recognition. 

Recently, the department acquired a PHI Quantes XPS system, the first in Africa and one of only 20 in the world. 

Creating better phosphor 

“The Quantes XPS system uses X-rays to determine the chemical composition of molecules on the surface of a sample. The system is unique in the sense that it also has an extra X-ray source that can determine the chemical state below the surface, which was not possible in the past.  This will help us to dictate the position of defects in our phosphor materials that will consequently enable us to create better phosphor for solid state lighting as well as solar cell applications,” explains Prof Hendrik Swart, Senior Professor in the Department of Physics, who also holds the SARChI Chair in Solid State Luminescent and Advanced Materials.

After he had the opportunity to observe the system in the factory in Chigasaki, Kanagawa, Japan, where he attended a conference, Prof Swart was very impressed by its performance. He discussed it with Prof Koos Terblans, Head of the department, and other colleagues, and started making plans to buy the system. 

When the department first bought the X-ray photoelectron spectroscopy (XPS) system in 2007/2008, it became the national facility on XPS measurements. Not only is this an upgrade of the XPS system bought 14 years ago, but the new system will enable the department to do more measurements. “The number of samples that we have to handle has just become too much for one system. The new system’s increased capacity for making measurements addresses this challenge and it also gives UFS scientists and postgraduate students more time to spend on fundamental measurements to develop research of a higher level,” says Prof Swart.

(The Quantes XPS system. Photo:Supplied)

Explaining about the measurements, Prof Swart says: “This advanced X-ray photoelectron spectroscopy (XPS) instrument has the capability to analyse the very small area that the user is interested in and a large area of the uniform sample surface. The two different types of X-ray sources – the hard X-ray source and the more conventional soft X-ray source – can be switched automatically, allowing users to analyse the same area and/or points of a sample. The PHI Quantes XPS system ensures the availability of superior features such as automatic analysis, automatic sample transfer, turnkey charge neutralisation, and advanced data processing.”

“This XPS instrument is designed to pioneer new methods and applications transcending conventional ideas of what is possible.”

Optimising efficiency of materials

Prof Swart says the Department of Physics, especially the Research Chair in Advanced and Luminescent Materials, is developing new high-technology materials on a daily basis. “It is very important to know the chemical composition and defect distribution of the materials in order to add value to the fabrication of these materials,” he adds.

“The distribution of these defects is vital for the efficiency of the phosphor materials. If we know where these defects are located, we can determine the mechanisms of the light output coming from these phosphors,” describes Prof Swart.

Research conducted as part of the Research Chair in Solid State Luminescent and Advanced Materials will benefit significantly from this new system.

(Prof Koos Terblans, Head of the Department of Physics next to the Quantes XPS system. Photo:Supplied) 

“We are currently concentrating on phosphors as sensors (temperature), light-emitting diodes (LEDs), and solar cells, where we optimise the efficiency and durability of these materials. Any new knowledge, which I believe the PHI Quantes XPS system will provide us, will help us to reach our goal much quicker,” he says. 

Apart from the positive impact on research, the PHI Quantes XPS system will also be a benefit to society in the long term. Improved LEDs can be used to save electricity, and better solar cells can help to generate electricity, to mention but two examples. 

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept